Last Updated on December 11, 2024 by The Health Master
USFDA
Granules India, a leading pharmaceutical company, has recently faced a setback in its US operations. The US Food and Drug Administration (USFDA) has issued an Official Action Indicated (OAI) classification for its Gagillapur facility in Hyderabad, Telangana.
This follows an inspection conducted earlier in September that resulted in six Form 483 observations.
What is an OAI?
An OAI is a serious regulatory action issued by the USFDA that indicates potential violations of US drug laws.
It often precedes warning letters or other enforcement actions.
Granules India’s Response
In response to the OAI, Granules India has taken the following steps:
- Detailed Response: The company has submitted comprehensive responses to the six observations raised by the USFDA.
- Comprehensive Evaluation: Granules India has initiated a thorough evaluation of its Gagillapur facility to identify and address any potential compliance gaps.
- External Expert Consultation: The company is seeking guidance from external subject matter experts to enhance its quality and compliance standards.
Impact on Granules India
While the OAI could potentially impact the company’s US operations, Granules India remains optimistic about resolving the issues and regaining compliance.
The company’s proactive approach and commitment to quality and safety are expected to mitigate the impact of this regulatory action.
Key Takeaways
- Granules India’s Gagillapur facility has received an OAI from the USFDA.
- The OAI was issued following an inspection that resulted in six Form 483 observations.
- Granules India is taking proactive steps to address the USFDA’s concerns.
- The company’s future US operations may be impacted by this regulatory action.
-
What is a Form 483?
A Form 483 is a document issued by the USFDA to detail objectionable conditions observed during an inspection.
-
What is the significance of an OAI?
An OAI indicates that the USFDA has identified serious violations and may take further enforcement actions.
-
How might this affect Granules India’s stock price?
Regulatory actions like OAIs can negatively impact a company’s stock price. However, the extent of the impact depends on various factors, including the severity of the violations and the company’s respons
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued Form 483 with 5 observations to Alembic
USFDA issued Form 483 with 7 observations to Dr Reddy’s
USFDA issued Form 483 with 4 observations to Shilpa Medicare
USFDA concludes inspection at Granules India with zero observations
USFDA inspection concluded at Alembic Pharma with no observation
MSMEs Commit to Revised Schedule M for Drug Quality
CDSCO Panel approval granted for Anti Cancer Drug Pertuzumab
India drops Anti Dumping probe on Mono Ethylene Glycol
Kerala Drug Control Department Goes Digital: A New Era of Efficiency
NPPA’s ceiling price for Methylprednisolone Upheld
Hospital caught overcharging for Medicines: Hyderabad
Standards for 214 Critical Medical Devices to be developed
FDA Maharashtra cracks down on 15 Medical Stores
Ceiling Price for Acyclovir 800 mg Tablets upheld
Strengthening drug security through Pharmaceutical Supply Chain
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
